PharmaShots Interview w Recce CEO James Graham

James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.

AusBiotech Journal 2021 Vol 31

A REVOLUTIONARY APPROACH against antimicrobial resistance

Recce tapping European investor interest

Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Recce tapping European investor interest

Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Proactive Investors – The smart money in medicine: the silent pandemic

Recce Pharmaceuticals is working on a solution.

Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives

Recce Pharmaceuticals (ASX:RCE) selects CMAX for phase I/II UTI clinical trial

Recce Pharmaceuticals boosts finances with A$6.21 million in R&D rebate payments

For this pharma boss, fishing is an experience in positivity

Recce Pharmaceuticals (ASX:RCE) granted notification of intent for Australian patent